CHICAGO — In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in ...

The treatment seemed simple, too simple. Instead of chemotherapy, I was to get infusions of an immunotherapy drug, Keytruda. Immunotherapy boosts the body’s immune system to fight the cancer cells and ...

Delpharm has increased its capacity by acquiring and installing a new, fully Annex 1 compliant, sterile filling line, significantly increasing its production capacity for sterile vials or ...

The FDA granted Merck’s application priority review on February 25, 2025, with approval following on June 13, 2025, based on interim results from Keytruda’s Phase 3 KEYNOTE-689 trial.

VIENNA, Va., June 18, 2025--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.

FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients FDA ...

The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC ...

FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval Multikine reduced the risk of death by 66% compared to standard of ...

The treatment seemed simple, too simple. Instead of chemotherapy, I was to get infusions of an immunotherapy drug, Keytruda. Immunotherapy boosts the body’s immune system to fight the cancer cells and ...

As a first-line treatment, Trodelvy combined with Keytruda lowered the risk of disease progression by 35% in patients with an aggressive type of breast cancer in a late-stage trial.

Patients with obesity who choose to self pay will soon be able to access the complete range of Zepbound single-dose vials, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Patients on ...